The CEO received total compensation of $8,823,502 in 2025, which is very high for a medical-device/life-science-tools company with a $350 million market cap trading near its 52-week low of $0.87; benchmarking a CEO role at this market cap band in the sector indicates this figure is substantially above what peers at a comparable company size would typically pay, raising the individual CEO threshold concern under policy. On top of the regular annual equity grant, the board awarded the CEO a special one-time retention grant of 3,000,000 restricted stock units (worth approximately $3.9 million at grant) in July 2025, even as the stock had declined roughly 49% over three years and underperforms the IHI — iShares US Medical Devices ETF by approximately 42.9 percentage points over that period; this large discretionary award provides significant above-benchmark variable pay at a time when shareholders experienced substantial losses, failing the pay-for-performance alignment test under policy. Although the prior Say on Pay vote received 98.29% support, which normally favors a FOR vote, the combination of an oversized total pay package relative to the company's market cap, a special one-time retention grant piled onto regular equity awards during a period of severe stock underperformance versus IHI, and incentive payouts at 160% of target while the stock trades near its 52-week low collectively indicate that variable pay is not meaningfully aligned with shareholder outcomes, warranting an AGAINST vote.

The proxy filing does not disclose auditor tenure or a fee breakdown table, so neither the tenure trigger (25 or more years) nor the non-audit fee ratio trigger (non-audit fees exceeding 50% of audit fees) can be applied; per policy, when tenure and fee data are not available we vote FOR and note the absence of disclosure as a minor negative factor. PricewaterhouseCoopers LLP is a Big 4 firm fully adequate for a company of LAB's size and complexity, and no material restatement attributable to audit failure is disclosed.